EN DE

Clever Leaves Holdings Inc (CLVR) Fair Value & Analysis

Healthcare · US · Market cap $350

CL Clever Leaves Holdings Inc logo Clever Leaves Holdings Inc CLVR · US
Price$0.0006
Fair Value$0.0006
Upside+0.0%
Quality40/100
Watch Clever Leaves Holdings Inc for free, get notified when fair value or trend changes. Watch for free
Mixed Growth
Loss-making · -102.8% net margin
Low debt · negative free cash flow
Trails peers (3/8)
Narrow moat 3/100
Evidence: Low Range $0.0006 – $0.0006 Share as image

Fair value as of: Aug 13, 2026

From 1 valuation models · updated 4 days ago

Fair value updated Aug 13, 2026, revised from $0.0001 to $0.0006 (+500.0%) since Jul 29, 2026.

Below-average quality, currently priced close to our fair value.

What matters now

  • The price sits close to our fair value, market and models broadly agree here, little valuation tension.
  • Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual.
Share this valuation: 𝕏 WhatsApp

Price vs Fair Value (5 years)

$3,456 $0.0006 Fair Value $0.0006 Jul 2020 Aug 2026

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Aug 13, 2026.

How to read this chart

60‑month range $0.0006 – $3,456 · the $0.0006 price screens below the $0.0006 fair value. Dashed = 300-day average. As of Aug 13, 2026.

Full chart & analysis →

Which stocks are undervalued right now? Check free Discover now →

Analysis

Clever Leaves Holdings Inc (CLVR) currently trades at $0.0006, while our model-based Fair Value estimate is $0.0006, implying the stock looks roughly 0.0% fairly valued today. The Quality Score stands at 40/100 (below-average quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: low), always confirm before acting.

Trailing-twelve-month revenue stands at $17.4M. Revenue grew 5.4% year over year. It earns a return on equity of -61.3%. The balance sheet holds a net cash position of $4.7M. Fundamentals as of Aug 13, 2026

For context, the median of 10 Healthcare peers we cover trades at -49% fair-value upside, at 0%, CLVR screens cheaper than that median.

Fair Value models

Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.

Model Bear Bear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull Bull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. Evidence
Highest evidence
NCAV (Graham) $0.0004 $0.0006 $0.0009 50
All 1 models by family
Asset-Based
NCAV (Graham) $0.0004 $0.0006 $0.0009 50

Notify me when CLVR reaches fair value

Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click.

Key figures & financial health

Revenue (TTM) $17.4M
Revenue growth (YoY) +5.4%
Net margin -103%
Return on equity -61.3%
Free cash flow −$11.5M FY2023
Operating margin -106%
More key figures
EPS (TTM) $-4.21
Net cash $4.7M FY2023

Figures from reported company fundamentals · as of Aug 13, 2026. TTM = trailing twelve months.

Quality Score breakdown

Overall quality 40/100

Of which business quality 41 · Market factors (momentum, volatility) 20

Profitability 15
Margins and returns on capital today
Quality Growth 87
Are margins and returns improving?
Cashflow 3
Earnings quality: real cash, not paper profit
Fin. Strength 68
Balance sheet, leverage, solvency risk
Investment 100
Disciplined investing over empire-building
Low Volatility 50
Calm price path (market factor)
Momentum 11
Price trend over the last 3–12 months (market factor)
52W Momentum 0
Distance to the 52-week high (market factor)
Net Issuance 0
Buybacks instead of dilution

Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.

About the company

Clever Leaves Holdings Inc. operates in the botanical cannabinoid and nutraceutical industries. The company operates through two segments, Cannabinoid and Non-Cannabinoid.

Full company description

Clever Leaves Holdings Inc. operates in the botanical cannabinoid and nutraceutical industries. The company operates through two segments, Cannabinoid and Non-Cannabinoid. The Cannabinoid segment cultivates, extracts, manufactures, commercializes, and distributes cannabinoid products comprising cannabis flowers, cannabidiol isolates, full spectrum and standardized extracts, and dry smokable flowers internationally. The Non-Cannabinoid segment formulates, manufactures, markets, sells, distributes, and commercializes nutraceutical and other natural remedies, wellness products, detoxification products, and nutritional and dietary supplements for mass retailers, specialty and health retailers, and distributors in the United States. It also produces extracted products, including isolates, crude oil extracts, and oral solutions; and tetrahydrocannabinol flowers. The company serves retail distributors, pharmaceutical and cannabis companies, and pharmacies. Clever Leaves Holdings Inc. was founded in 2017 and is based in Tocancipá, Colombia.

Company description, as reported by the company or data provider.

Revenue & earnings trend

FY2019 – FY2023 · reported fiscal years

Clever Leaves Holdings Inc reported revenue of $17.4M in FY2023 versus $7.8M in FY2019, a compound +22.1%/yr. Reported net income was −$17.9M in FY2023.

Growth Quality 34/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Latest Revenue (FY 2023)
$17.4M
Latest YoY
+6.1%
Avg. growth/yr (3Y) Measures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump.
+12.9%
Revenue +22.1%/yr
FY19 $7.8M
FY20 $12.1M
FY21 $15.4M
FY22 $16.4M
FY23 $17.4M
Net income
FY19 −$46.0M
FY20 −$36.1M
FY21 −$45.6M
FY22 −$66.1M
FY23 −$17.9M

Watch CLVR: get an alert when its fair value changes →

Share or link this analysis
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Cite: Fair Value Calculator (2026). "Clever Leaves Holdings Inc Fair Value". https://www.fairvalue-calculator.com/stock/CLVR

Peer Group

Drug Manufacturers - Specialty & Generic · 625 stocks

How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.

Quality Score 41 · Bottom 25%
Fair Value upside −0% · Above median
Return on assets -23% · Bottom 25%
Net margin (TTM) -103% · Bottom 25%
Operating margin (TTM) -106% · Bottom 25%
Revenue growth 5% · Above median
Debt / equity 0.03× · Lower than median

Snowflake

Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.

VALUE 33 · sector 7
FUTURE 27 · sector 20
PAST 0 · sector 24
HEALTH 99 · sector 96
DIVIDEND 0 · sector 32

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.

Similar stocks

10 more Drug Manufacturers - Specialty & Generic stocks, each showing price versus our Fair Value estimate (as of Aug 13, 2026).

Stock Price Fair Value vs Fair Value
Jiangsu Hengrui Pharmaceuticals Co 600276 ¥53.76 ¥25.94 -52%
Sun Pharmaceutical Industries Limited SUNPHARMA ₹1,944 ₹989.50 -49%
Divi's Laboratories Limited DIVISLAB ₹8,500 ₹1,932 -77%
Torrent Pharmaceuticals Limited TORNTPHARM ₹4,915 ₹1,163 -76%
PharmaEssentia Corporation 6446 1,440 TWD 233.93 TWD -84%
Cipla Limited CIPLA ₹1,463 ₹1,001 -32%
Zydus Lifesciences Limited ZYDUSLIFE ₹1,167 ₹703.32 -40%
Lupin Limited LUPIN ₹2,281 ₹2,477 +9%
Mankind Pharma Limited MANKIND ₹2,433 ₹983.11 -60%
Dr. Reddy's Laboratories Limited DRREDDY ₹1,200 ₹874.79 -27%

Compare Clever Leaves Holdings Inc with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks

Frequently asked questions

Is Clever Leaves Holdings Inc (CLVR) overvalued or undervalued?
As of Aug 13, 2026, our model estimates a fair value of $0.0006 versus a price of $0.0006, about +0% (fairly valued).
What is the fair value of CLVR?
Our model-based fair value for Clever Leaves Holdings Inc is $0.0006 (as of Aug 13, 2026), built from audited fundamentals. The current price is $0.0006.
What is the quality score of CLVR?
Clever Leaves Holdings Inc has a Quality Score of 40/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the revenue of Clever Leaves Holdings Inc (CLVR)?
Clever Leaves Holdings Inc reported trailing-twelve-month revenue of about $17.4M (latest available figure, as of Aug 13, 2026).
What is the net profit margin of CLVR?
The net profit margin of Clever Leaves Holdings Inc is about -102.8%, meaning it is currently running at a net loss. Based on the latest reported figures.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.

14 days Pro free · no card

Track Clever Leaves Holdings Inc and try Pro for 14 days

One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.

Zero risk: nothing is ever charged. After 14 days you decide whether to stay.